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181* Development of a novel tool for the rapid detection of neutrophil
elastase as a marker of inﬂammation within the clinic
L. Martin1, K.L. Mofﬁtt1, J.S. Elborn2, B. Walker1. 1Queen’s University, Belfast,
Biomolecular Sciences Research Group, School of Pharmacy, Belfast, United
Kingdom; 2Queen’s University, Belfast, CF and Airways Microbiology Research
Group, Belfast, United Kingdom
Neutrophil elastase (NE) is a biomarker of infection and inﬂammation which
has been shown to correlate with the severity of several respiratory diseases,
including cystic ﬁbrosis (CF). Utilising our unique Protease-Tag molecules, we have
developed a novel methodology for the capture and detection of active proteases
in complex samples such as CF sol. The aim of this work was to provide initial
clinical validation of the NE-Tag assay in CF.
Sputum (n = 45) was recovered from CF patients hospitalised for acute exacerbation.
Sol was recovered and analysed for NE activity using the NE-Tag ELISA and two
ﬂuorogenic substrate-based assays [1. Suc-AAPV-AMC (Sigma) and 2. Innozyme™
Immunocapture assay (Calbiochem)]. NE activity between assays and with a range
of clinical parameters was correlated.
A highly signiﬁcant correlation was shown between assays. NE activity (NE-
Tag) further correlated appropriately with clinical parameters: inversely with FEV1
(p = 0.036) and positively with CRP (p = 0.035), neutrophils and total white cell
counts (p = 0.000). The Innozyme™ assay showed similar correlations with the
clinical parameters (with the exception of CRP). No correlations with any of
the clinical parameters were observed when NE was measured using the standard
ﬂuorogenic substrate.
NE as a primary efﬁcacy endpoint in clinical trials or as a marker of inﬂammation
within the clinic has been hampered by the lack of a robust and simple to use
assay. The NE-Tag assay has advantages over the InnoZyme™ assay in terms of
time, ease of use and no dependency on a kinetic readout; it has also the capability
of being transferred to a lateral ﬂow device for routine monitoring.
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Introduction: Cystic ﬁbrosis is a frequent genetic disease with pulmonary inﬂam-
mation, enhanced by repeated infections. This early inﬂammatory process leads to
bronchial alterations and pulmonary functional defects.
The aim of the study was to compare oxidative stress markers [Malondialdehyde
(MDA)] in exhaled breath condensate in children with cystic ﬁbrosis vs. normal
controls.
Patients and Methods: In this prospective case-control study, 15 children with
cystic ﬁbrosis were matched with 30 controls regarding age and sex. In both
groups exhaled breath condensate, pulmonary function tests, urine and blood
samplings were performed on day 1 AM. MDA levels were determined by Gas
Chromatography. Repeat exhaled breath condensate measurements were performed
on day one PM and 3 months later in CF patients.
Results: Median [range] age of patients was 9.6 [6.2–12.1] yrs, the sex ratio was
M:F = 1:0.66. The MDA determinations were reproducible in both groups with a
coefﬁcient of variation of 6.3% (2 assays per sample). Median EBC MDA level on
day 1 AM was 1.40 [0.55–7.53] in CF patients versus 0.80 [0.00–4.65] in controls
(p< 0.05). In CF patients day 1 PM MDA levels were 0.95 [0.26–2.68] (NS vs. day
1 AM). MDA levels 3 months later showed a further increase in oxidative stress in
CF patients: 1.62 [0.07–31.26] (p< 0.05 vs day 1).
Conclusion: Pulmonary oxidative stress markers in exhaled breath condensate are
increased in children with CF compared to controls, with good reproducibility.
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Background: Previous studies report patients with cystic ﬁbrosis (PWCF) have
persistently elevated circulating pro-inﬂammatory serum cytokine concentrations.
In other chronic diseases, these cytokines have been associated not only with
physiological and metabolic effects but also psychological ones. This study analyses
the serum circulating cytokines in PWCF and their clinical relationships, including
the 9 domains of health assessed in the Cystic Fibrosis Questionnaire-Revised
(CFQR).
Methods: Circulating pro-inﬂammatory cytokines concentrations (IL-6, IL-8,
TNF-a (cachexin) and IL-1b) were measured in the supernatant of whole blood
samples obtained from stable adult PWCF >5 weeks free from an infective
pulmonary exacerbation, and a healthy control population. Cytokine concentrations
were correlated against CRP, CFQR, serum [1,25OHD3], FEV1% predicted,
azithromycin use and neutrophil count using a Bonferroni correction.
Results: 68 PWCF and 57 controls were recruited. The pro-inﬂammatory cytokines
were not signiﬁcantly higher in PWCF. There were no signiﬁcant correlations be-
tween [cytokine] and the 9 domains of health, azithromycin use, serum [1,25OHD3]
or neutrophil count. As expected physiologically, IL-6 correlated signiﬁcantly with
CRP (r = 0.69, p< 0.001), TNF-a correlated with reduced BMI (r = 0.274, p = 0.02)
and the CFQR had multiple signiﬁcant correlations with FEV1% predicted, BMI
and age in PWCF (p< 0.005).
Conclusion: In our cohort of stable adult PWCF there was no association between
baseline cytokine concentrations and psychological well being. The lack of a
signiﬁcant elevation in resting cytokine levels in PWCF may contribute to this.
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Introduction: The opportunistic fungus Aspergillus fumigatus (Af ) colonizes a
signiﬁcant fraction of cystic ﬁbrosis (CF) patients, with some further progressing
towards allergic bronchopulmonary aspergillosis (ABPA), a type I hypersensitivity
response. ABPA signiﬁcantly impacts short- and long-term prognoses in CF, yet may
be avoided by early diagnosis and treatment. However, the diagnosis of CF-ABPA is
clinically challenging, due in large part to the absence of an objective biological test.
Since blood basophils play a major role in allergic responses, we hypothesized that
discrete changes on their surface activation pattern could discriminate CF patients
with ABPA from those without.
Method: We used a direct ﬂow cytometry assay to measure surface CD203c levels
on blood basophils, at baseline and upon rapid in vitro activation with Af -speciﬁc
allergen, in 3 groups of subjects: (A) CF patients with chronic Af infection but
without ABPA (N= 4); (B) CF-ABPA patients (N = 7); and (C) healthy controls
(N = 7).
Results: In the CF-ABPA group, but not other groups, basophil CD203c levels
increased speciﬁcally upon Af allergen stimulation (P< 0.004). Basophil CD203c
levels upon Af allergen stimulation provided excellent predictive value for discrim-
inating CF-ABPA from CF patients with chronic Af infection but without ABPA
(area under the receiver operating characteristics curve = 0.95, P< 0.009).
Conclusion: These results support the notion that basophils play a role in the
pathogenesis of CF-ABPA and can be used to diagnose this condition with a simple,
clinically-relevant, blood assay.
